<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 72 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page71.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=72">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 72 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 72</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=72"><img src="../thumb/72.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Central Nervous System - 1.6                                                    2020-04 / 41
       with concom.glyburide/ metformin & pioglitazone, phenytoin lev.to   Warnings and special precautions: Use in pregn. if benef.out-  Dosage: Init. with clinic.effect.dos.admin.in 2 div.dos. May be incr.
       be monit. with concom.use.    weighs risk, pt.to be inform.of potent. harm to foetus if used dur.  depend.on clinic.respons.
       Drug interactions: Poss.incr.phenytoin plasma conc., phenytoin &   pregn./becom. pregn., poss.excret.in breast milk, syndr.consist.of   Monother: Adults & elderly: Init: 600 mg/day in 2 div. dos., good
       carbamazepine decr.plasma conc., decr.ser.digox., plasma clear.of   ac. myopia assoc.with second.clos.angl.glauc. even in paed. pts.  therapeut.eff.at 600-2 400 mg/ day. If indic.incr.by max.of 600 mg/
       OC’s oestrog. compon.incr.signif.  in which case ther.to be discont., OC effic.poss.decr., eval.ser.bicar-  day increm.at wkly interv.from start.dos.to desir.clinic.respons. Most
       TOPAMAX, Janssen Pharmaceutica [P/S]  bon.lev.dur.ther., monit. phenytoin /digoxin/Li lev., diab. contr.monit.   pts.controll.on 900-1 200 mg/day.
                                                                  Adjunct.ther: Adults: Init: 600 mg/day in 2 div. dos., good thera-
                                     with concom.metformin./pioglitazone/glyburide, avoid concom.CNS
       Topiramate.                   depress. & alcoh./agents predispos. to nephrolithias., hypotherm.  peut.eff.at 600-2 400 mg/day. If indic.incr.by max.of 600 mg/day
       Indications: As monother.in new.diagn.epilep./ convers.to monother.  with concom. valproic acid when init.ther./incr.dly.dos., grad. withdr.,   increm.at wkly interv from start.dos.to desir.clinic.respons. Poss.
       in pts.with epileps., adjunct. ther.in adults & childr.over 4 yrs.when   ren./liv.impairm., adeq.hydrat.esp. prior/dur exerc. & expos.to warm   reduct.in concom.anti-epilept.meds.if 2 400 mg/ day giv. Dly.dos.
       inadeq. contr. by convent.first line anti-epilept.meds.for partial onset   temp., decr. sweat.& hypertherm.poss.esp.in young childr. expos.  above 2 400 mg not stud.
       seiz.with/without second.gen.seiz., seiz. assoc.with Lennox-Gastaut   to high ambient temp., monit.mood/signs of suicide ideat., incr.ren.  Childr.: In mono/ adjunct.ther.init. at 8-10 mg/kg/ day in 2 div.dos. In
       syndr.& prim. generalis. tonic-clonic seiz.  stone format.risk esp.where predispos. to nephrolithias., avoid con-  adjunct.ther.trial in paed.pts.3-17 yrs: (in which targ.dly.dos: 46mg/
       (S3) TABS. 30/2.5/0236, 0237, 0238, 0239.  com.meds. predispos. to nephrolithias., chron.untreat.metab. acidos.   kg/day) median dly. dos.of 31 mg/kg/day. 1 mnth -&lt;4 yrs: (where
       822515-008: 25 mg, 60, R488,46  incr.nephrolithias/nephrocalcinos.risk, chron. metabol.acidos.reduc.  targ.dly. dos.was 60 mg/kg/day) Fin.dos in 56% of pts: 55 mg/kg/
       822523-019: 50 mg, 60, R768,42  growth rates in paed. pts. & leads to nephrolithias.& incr.fract. risk,   day. If clinic.indic.incr. dos.by max. 10 mg/kg/day increm.at approx.
       822531-003: 100 mg, 60, R1 295,38  condits./ ther.predispos.acidos.addit.to bicarbon. lower. effs., vis.  wkly. interv.from start.dos.to max.dly.dos.60 mg/kg/day to achieve
       836753-003: 200 mg, 60, R1 970,94  field defects independ. of elev. intraocul.press., consid.discont.if   desir.clinic.respons. Und.adjunct.& monother. when normalis.by body
       (S3) SPRINKLE CAPS, 32/2.5/0662, 0663, 0664  vis.prob. occ., lact. intol., safety in pregn.& lactat.not est., human &   weight, clear. decr. with age of child.
       878014-004: 15 mg, 60, R337,05  anim.reproduct.tox.report.  Contraindications: Not recomm.in lactat., MAOI, no studies in
       878022-007: 25 mg, 60, R337,05  Interactions: Poss.incr.phenytoin plasma conc., incr. adverse effs.  childr.bel.1 mnth.
       890728-003: 50 mg, 60, R569,05  with concom.lamotrigine, phenytoin & carbamazepine decr.plasma   Side-effects: Hypersens.reacts.incl.anaphylax., angioed.involv. lar-
       Dosage: Init.at low dos.titrat.to effect.dos. Tabs. not to be broken.   ynx/lips/glottis/eyelids, ser.skin reacts.incl., Stev.-Johns.syndr./tox.
       Sprinkle caps: Swall.whole/ sprinkle cont.on small amnt.soft food &   conc., dos. depend.signific.incr.clear.of oestrog. compon. of OC, syst.  epiderm. necrolys./ erythema multiforme, incr.seiz.freq.with abrupt
                                     expos.of Li.poss.incr.at dos. &gt;200 mg, decr.ser.digox., hydrochlorothi-
       swallow immed. Do not chew.                                withdr., suic.ideat./behav., somnol., headache, dizzin., diplop., GI
       Monother: Discont.grad.at 1/3 of concomit.AED dos.every 2 wks.  azide incr. Cmax & AUC, incr.C max & AUC of metformin, AUC 24 of gly-  disturbs, fatig., bld. dyscras., hepatit., hepat.encephalopathy, joint
                                     burine decr., hyperammonaem.with/ without encephalopathy with
       recomm.unless safety concerns require abrupt withdr.Topiramate lev.  concom.valpr.acid, incr. C max & AUC with propanolol., incr.AUC with   swell., myalg., arthralg., proteinur., interstit. nephrit./lung dis., ren.
       will incr. when enzyme induc.drugs are withdr. Dos.decr. may be reqd.  diltiaz., decr. AUC & DEA of diltiaz., incr.AUC of flunarazinine, AUC   fail., dyspn., pulm.oed., asthma, bronchosp., hyponatraem., hypo-
       if clinic.indicat. Adults incl. elderly: Init: 25 mg nightly x1 wk.incr.at   & C max incr.of nortriptyline metabol., AUC incr.in reduc  thyroid., fol.acid.defic., vis.disturbs., seiz., CNS effs.incl. depress.
       1-2 wkly. interv.by increm.of 25-50 mg/day admin. in 2 div. dos. guid.  consciousn. lev., psych./card.disords., vertigo, hypertens., pancreatit.,
       by clinic.outcome. Recomm. init. monother.target dos.is 100 mg/day.   TOPLEP, Ranbaxy [P/S]  alopec., SLE, asthen, decr.bone miner.dens./ osteopen./ osteoporos./
       Max. recomm. dly.dos.500 mg/day. Childr.2 yrs and over: Init. 0,5-  Topiramate.  fract.in pts.on longt.ther., card. conduct.impairm., arrythm., AV block.
       1 mg/kg nightly x1 wk.incr.at 1-2 wkly.interv. by increm.of 0,5-1 mg/  Indications: Adjunct.ther.for adults & childr.over 4 yrs.when inadeq.  Warnings and special precautions: Discont. ther./init.alter.
       kg/day admin. in 2 div.dos.guid.by clinic.outcome. Recomm. init.tar-  contr.by convent.first line anti-epilept.meds.for partial onset seiz.with/  treatm.if sev.hypersens. S&S devel./sev.skin reacts., prev.carbamaz-
       get dos range is 3-6 mg/kg/day. Dos. of up to 500 mg/day in recent.  without second.gen.seiz., seiz.assoc.with Lennox-Gastaut syndr.&   epine hypersens., multi-organ hypersens.reacts., pts.to be made
       diagnos.part. onset seiz.in childr.record.  prim. generalis.tonic-clonic seiz., monother. in newly diagn.epilep./  aware of early tox.signs & phys.to be alert., concom.alcoh., discont.
       Adjunct.ther: Adults: Init: 25-50 mg nightly x1 wk. Subseq.at wkly.  convers.to monother. in pts.with epilep.  grad.or und.cover of suit. meds.& close supervis.if abrupt discont.
       interv.incr.by 25-50 mg/day & admin.in 2 div.dos.guid.by clinic.out-  (S3) TABS. A40/2.5/0348, 0349, 0350, 0351  necess., ser.birth defects report., weigh benef./ risk if a woman be-
       come. Usual tot. dly.dos: 200-400 mg in 2 div.dos. Max.dos: 800 mg/  708389-001: 25 mg, 60, R182,85  com./plans pregn.dur.ther.esp. dur.first trimest., minim.effect.dos.to
       day. Childr.4 yrs and over: Recomm.tot. dly. dos.is approx.5-9 mg/  708390-001: 50 mg, 60, R351,90  be giv., monother. advis.in women of child-bear.age, poss. aggra-
       kg/day in 2 div.dos. Init. 25 mg or less, based on range of 1-3 mg/kg/   708391-001: 100 mg, 60, R571,55  vat. of illness if anti-epilept.treatm.interrupt. dur. pregn., pts.to be
       day at night.x1st wk. Incr.dos.at 1 or 2 wk.interv. by increm. of 1-3   708392-001: 200 mg, 60, R802,80  counsel.re incr.malform.risk/ antenat.screen., folic acid defic.may
       mg/ kg/day admin.in 2 div.dos. guid. by clinic.outcome.  Dosage: Init.at low dos.titrat.to effect.dos. Tabs. not to be broken.  contrib.to incr. birth defects theref.supplementat.recomm., to prev.
       Contraindications: Safety & effic.in childr.und. 2 yrs.not est.,   Adjunct.ther.: Adults: Init: 25-50 mg nightly x1 wk. Subseq.at wkly.in-  bleed.disords.in newborn, vit.K1 recomm.for mother dur.last wks.of
       pregn.& lactat.               terv.incr.by 25-50 mg/day & admin.in 2 div. dos.guid.by clinic.outcome.   pregn.& to newborn, cross.placenta & excret.in breast milk, clinic.
       Side effects: V.common: Depress., paraesthes., somnol., dizzin.,   Usual tot. dly.dos: 200-400 mg in 2 div.dos. Max.dos: 800 mg/day.  respons.monit.dur.pregn./post-part., imp.ren.funct., admin.und.med.
       naus., diarrh., fatig., weight decr. Common: Anaem., hypersens.,   Childr.4 yrs and over: Init.25 mg x1st wk.incr. dos. at 1 or 2 wk.interv.  supervis., consid.discont.in case of hepatit./ evid.of signif.bone marr.
       anorex., decr. appetit., bradyphren., insomn., express.language   by increm.of 1-3 mg/kg/day admin.in 2 div.dos.if more than 25 mg/  depress. appears, monit.for suic.ideat./behav.& appropr.treatm., ad-
       disord., anx., confus.state, disorientat., aggress., alt. mood, agitat.,   day. Recomm. dos.thereaft.5-9 mg/kg/day in 2 div.dos. Dos.titrat.  dit. non-hormon. contracept.recomm., elderly, monit.ser.sod.lev.bef.
       mood swings, anger, abnorm. behav., att.disturbs., memory impairm.,   guid.by clinic.outcome.  init.ther.& regul.aft.in pre-exist.ren.condit.assoc.with low Na lev./
       amnes., cognit.disord., ment.impairm., imp.psychmot. skills, convuls.,   Monother: Consid.effs.of concom.ADE’s withdr.on seiz.contr. Un-  concom. Na-low.meds., clinic.sympt.suggest.of hyponatraem., pre-
       abnorm.co-ordinat., trem., letharg., hypoaesthes., nystagm., dysar-  less abrupt withdr.reqd.for safety concerns. discont.concom.ADE   exist.conduct.disturbs. eg. dysrythm./ AV block, OC’s, not stud.in
       thr., bal.disord., dysarthr., intent.trem., sedat., blurr.vis., diplop., vis.   at approx.1/3 of concom. dos.every 2 wks. Toplep lev.will incr.when   sev.hepat. impairm., concom.phenytoin., monit.ser.conc.of concurr.
       disturbs., vertigo, tinnit., ear pain, dyspn., epistax., nas.congest., rhi-  enzyme induc.meds.are withdr.  anti-epilept.meds.if carbamazepine/other anti-epilept. with enzyme.-
       norrh., vomit., constip., upper abdom.pain, dyspeps., abdom.pain, dry   Adults: Init: 25 mg nightly x1 wk. Subseq.at 1-2 wkly. interv.incr.by   induc.propert.withdr.& replac.by Trileptal.
       mouth, stomach/ abdom. discomf., oral paraesthes., gastrit., alopec.,   25-50 mg/day admin.in 2 div. dos. guid.by clinic.outcome. Recom.init.  Drug interactions: Incr.CNS eff.with alcoh., poss. interacts.on high
       rash, prurit., arthral., musc. spasm/ twitch., myalg., musc.weakn.,   target dos.is 100 mg/day with max.500 mg.  dos.with drugs.metabol.by CYP2C19 eg. phenobarbit. & phenytoin,
       musculoskelet. chest pain, nephrolithias., dysur., pyrex., asthen., irri-  Childr.4 yrs and over: Init.0,5-1 mg/kg mg x1st wk.incr. dos.at 1 or   poss. interacts.with other concurr.anti-epilept.meds., reduc. plasma
       tabil., gait disturbs., feel. abnorm., malaise. Uncommon: Leucopen.,   2 wk.interv.by increm.of 0,5-1 mg/kg/day admin.in div.dos. Recomm.  lev.with viloxazine., decr. felodipine/ horm.contracept. AUC, decr.
       thrombocytopen., lymphadenopathy, eosinophil., metabol.acidos., hy-  init.targ. dos.3-6 mg/kg/day. Dos.titrat.by clinic.outcome.  plasma lev. with cert.meds.metabol.by CYP3A4 & CYP3A5.
       pokalaem., incr.appetite, polydips., suic.ideat./ attempt., hallucinat.,   Contraindications: Safety in childr.und.4 yrs.not est., pregn.& lactat.
       psychot. disord., audit.-/vis. hallucinat., apathy, lack of spontaneous   Side effects: Ac.myopia assoc.with second.clos. angl.glauc.even in   VALEPTIC, AI Pharm Ltd [P/S]
       speech, sleep disord., labil. affect., decr.libido, restlessn., cry., dys-  paed.pts., hyperchlorem.non-anion gap metabol.acidos., leucopen.,   Sodium valproate
       phem., euphor. mood, paranoia, perserverat., pan.attack, tearfuln.,   purpura, anaem., thrombocytopen., thromboembol.events, vir.infect.,   Indications: Gen.epilep.partic.with absence/ myoclon./ ton.-clon./
       read.disord., init.insomn., flat affect, abnorm. think., loss.of libido,   weight decr., anorex., psych.disords., psychomot.slow., diffic.with   aton.& mix.patt.seiz., part. epilep.with simple or complex seiz./sec-
       listless, middle insomn., distractibil., early morn.awaken., pan. re-  memory/conc., confus., depress., mood disturbs., personal. changes,   ond.gen. seiz & specif.syndr.eg.West & Lennox-Gastaut, treatm.&
       act., elev.mood, depress.lev.of consciousn., grand mal convuls., vis.  insom., agitat., cognit.probl., emot. lability, apathy, psychot.sympts.,   prev.of mania assoc.with bipol.disords.
       field defect, complex part. seiz., speech disord., psychomot.hyperact.,   hallucinat., aggress. behav., suicid.ideat/attempts, paresthes., atax.,   (S3) CR TABS, 44/2.5/0067, 0068
       syncope, sens.disturb., drool., hypersomn,., aphas., repetit.speech   dizzin., speech & relat.speech disords., trem., hyperkinesia, co-ordinat.  720026-001: 300 mg, 100, R391,07
       hypokines., dyskines., postur.dizzin,, poor sleep qual., burn.sensat.,   prob., vis.field defects., abnorm.vis., diplop., nystagm., ac.& second.  720027-001: 500 mg, 100, R645,07
       sensory loss, parosm., cerebell.syndr., dysaesthes., hypogeus., stu-  angle clos.glauc., conjunctiv., tinnit., hypotens., pharyngit./rhinit.,   Dosage: Take with/aft.food. Swall.whole without crush./chew.tabs.
       por, clumsin., aura, ageus., dysgraph-/-phas., periph. neuropathy,   pneumon., dyspn.,GI disturbs., incr.saliva product., hepatit.& hepat.  Admin.once/twice dly. Dly.dos. vary accord. to age & body mass. Op-
       presyncope, dyston., formicat., reduc. vis.acuity, scotoma, dry eye,   fail., gingivit., incr.sweat., prurit., skin reacts.incl erythema multiforme/  timum dos. main.determ.by seiz.contr. Valeptic formul. interchang.
       photophob., blepharosp., incr.lacrimat., photops., mydrias., presby-  Stev.-John. syndr./tox. epiderm. necrolysis & pemphigus, nephro-  with other convent.or prolong.release formulat.on equiv.dly.dos.ba-
       op., unilat.& neurosens.deafn., ear discomf., imp.hear., bradycard.,   lithias., dysur., urin.freq., incontin., ren.fail., haematur., fatig., injury  sis where adeq.contr. achiev.
       sinus bradycard., palpitat., orthostat.hypotens., hypotens., flush., hot   Special precautions: Condit./ther.predispos.to acidos., eval.bi-  Epilepsy: Adults: Start 600 mg/day in div.dos. where applic., incr.
       flush, exert.dyspn., paranas.sinus., hypersecret., dysphon, pancreatit.,   carbon.lev.dur.ther.& reduc.dos.or discont.if metabol.acidos.devel.&   by 5-10 mg/kg/day at wkly. interv.until contr.achiev.gen.betw. 1 000-
       flatul., GORD, low. abdom. pain, oral & fac.hypoaesthes., gingiv.  persists, chron. metabol.acidos.reduc.growth rate in paeds./leads to   2 000 mg/ day i.e.20-30 mg/day bm. Dos.may be furth.incr.in stages to
       bleed., abdom. distens., epigastr.discomf., abdom. tendern., saliv.  nephrolithias.& incr.fract.risk, potent. teratogenic. risk, contracept.  max.of 2 500 mg/day or one other anti-epilept.agent may be add.at a
       hypersecret., oral pain, breath odour, glossodyn., anhidros., urticar.,   effic.of OC’s poss. decr., OC’s to contain at least 50 ug of oestrog./   low dos. if adeq.contr.not achiev.aft.2 wks. Same pattern to be foll.in
       erythema, gen.prurit., macul.rash, skin discolourat., allerg. dermatit.,   use alt.non-hormon.contracept., avoid concom. meds.predispos.  pts.already receiv.other ther. Barbits.& benzodiazep.dos.to be reduc.
       swell.face, musculoskelet.stiffn., flank pain, musc.fatig., urin. calcul.,   to nephrolithias., hypospad. report.in male babies expos.in utero,   as Valeptic incr.if incr. sedat.occurs. Dos.of Valeptic & other agents
       urin.incontin., haematur., incontin., micturit. urgency, ren.colic/-pain,   remov.from plasma by haemodialys., grad.withdr., ren./hepat. im-  to be adjust.dur.stabilisat.per.giv.optim.contr.at low. poss.combin.dos.
       sex.-/ erect.dysfunct., hypertherm., thirst, sluggishn., periph. coldn.,   pairm., adeq.hydrat.esp.prior/dur.exerc.& expos. to warm temp.,   lev.or maint.optim.contr.with Valeptic alone.
       feeling drunk/-jitter., crystal urine, tandem gait, learn.disabil. Rare:   discont.if vis.probl.develop.  Treatm.& prev.of mania assoc.with bipol. disords: Recomm.
       Hyperchloraem. acidos., man., pan.disord., hypoman., aprax., circa-  Drug interactions: Poss.incr.phenytoin plasma conc., phenytoin &   init.dos: 1 000 mg/day. Incr.as rapid.as poss.to achiev.low.therap.
       dian rhythm sleep disord., hyperaesthes., hyposm., anosm., essent.  carbamazepine decr.plasma conc., decr.ser.digox., plasma clear.of   dos.produc. desir. clinic.eff. Adjust accord.to indiv.clinic. respons.
       trem., akines., unrespons. to stimuli, unilat.or trans. blindn., glauc.,   OC’s oestrog. compon incr.signific.  Est.prophylact.treatm.indiv.with low. effect. dos.
       accomodat.disord., alt.vis.depth percept., scintillat.scotoma, night   Missed doses: Once dly.dos.sched: Take dos. as soon as poss.
       blindn., amblyop., Raynaud’s phenom., hepatit., hepat.fail., abnorm.   TRILEPTAL, Novartis [P/S]  Skip miss.dos.if not rememb.until next day. 2xdly sched: Take dos.
       skin odour, loc.urticar., uret.calcul., fac. oed., decr. bld.bicarbon. Post   Oxcarbazepine  within 6 hrs if rememb., taking remain.dos.for that day at equally
       market: Neutropen., hyper-/ hypoammonaem., allerg.oed., hypera-  Indications: As monother.& adjunct.ther.in adults & childr aged   spaced interv. No doubl.of dos.recomm.
       monem. encephalopath., feel.of despair, abnorm. eye sensat., angle   1 mnth.& old: Part. seiz.with/without second.generalis. seiz.& gen-  Contraindications: Pregn.& lactat., act.liv.dis. incl.ac.& chron.hep-
       clos.glauc., conjunctiv. oed., eye movem.disord., eyelid oed., macu-  eral.tonic-clonic seiz.  atit./hepat.dysfunct.hist.esp. meds.-relat./hepat.porphyr., women of
       lopathy., myop., cough, Stev.-John. syndr./ tox. epiderm.necrolys.,   (S3) TABS. X/2.5/205, 206.  childbear. age. unless other treatm.ineffect./not tolerat.
       erythema multiforme, joint swell., limb discomf., nephrocalcinos.,   892484-008: 300 mg, 50, R354,11  Side effects: Sev.liv.damage/dysfunct., sev. pancreatit. somet.
       ren. tubul. acidos., gen.oed., flu-like illn., incr.weight.  892491-020: 600 mg, 50, R666,71  fatalit., thrombocytopen., allerg. reacts., CNS effs.incl.stupor/leth-</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page71.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page67.html">67</a>&nbsp;&nbsp;&nbsp;<a href="page68.html">68</a>&nbsp;&nbsp;&nbsp;<a href="page69.html">69</a>&nbsp;&nbsp;&nbsp;<a href="page70.html">70</a>&nbsp;&nbsp;&nbsp;<a href="page71.html">71</a>&nbsp;&nbsp;&nbsp;<a href="page72.html">72</a>&nbsp;&nbsp;&nbsp;<a href="page73.html">73</a>&nbsp;&nbsp;&nbsp;<a href="page74.html">74</a>&nbsp;&nbsp;&nbsp;<a href="page75.html">75</a>&nbsp;&nbsp;&nbsp;<a href="page76.html">76</a>&nbsp;&nbsp;&nbsp;<a href="page77.html">77</a>
             </td>
             <td width="35%"><a href="page73.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page73.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
